ESR1 and breast cancer: To test the selective antitumor activity of JA, we compared its anti-proliferative activities in a panel of breast cancer cell lines consisting of estrogen receptor (ER)-positive (MCF-7 and T47D) and triple-negative cells (MDA-MB-468).